The consortium, made up of the company ETAP-Lab, leader of the project, the company Plant Advanced Technologies PAT and the IMoPA-UMR 7365 CNRS laboratory of the University of Lorraine, announces the official launch of the BRYOFLAM project. This collaborative research program was selected by the Grand Est Region and the State as part of the “Regionalized I-Demo Collaborative Projects” program.
This research project, selected by the C2IME*, benefits from the support of the Grand Est Region and the State, which recognize the importance of scientific and technological innovation in the development of new therapies against inflammation.
The three-year BRYOFLAM project aims to discover new active molecules of plant origin to fight against inflammatory pathologies of the skin, the central and peripheral nervous system and the intestine.
Plant Advanced Technologies PAT, using its proprietary technologies, will produce plant extracts and molecules. These compounds will be evaluated using a wide variety of tests performed on relevant cellular and animal models.
The full press release and all the latest news from the PAT Group are online at www.plantadvanced.com
Plant Advanced Technologies is listed on Euronext Growth™- Paris
ISIN: FR0010785790 – Mnemonic: ALPAT
Reuters ALPAT.PA – Bloomberg: ALPAT: FP